Jack Hutter

Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial

Melinda Hamer, Katherine V. Houser, Amelia R. Hofstetter et al. · The Lancet · 2023 · 62 citations · Full text

Vaccination, Vaccine Safety, Vaccine Development +9

First-in-human assessment of safety and immunogenicity of low and high doses of Plasmodium falciparum malaria protein 013 (FMP013) administered intramuscularly with ALFQ adjuvant in healthy malaria-naïve adults

Jack Hutter, Paul M. Robben, Christine Lee et al. · Vaccine · 2022 · 25 citations · Full text

Vaccination, Global Burden, Vaccine Development +14

A three-antigen Plasmodium falciparum DNA prime—Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults

Marvin J. Sklar, Santina Maiolatesi, Noelle B. Patterson et al. · PLoS ONE · 2021 · 21 citations · Full text

Malaria, Immunology, Boost Vaccine +16

Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial

Michael Koren, Leyi Lin, Kenneth H. Eckels et al. · The Lancet Infectious Diseases · 2023 · 21 citations · Full text

Vaccination, Vaccine Safety, Vaccine Development +7

Bacteraemia due to Microbacterium paraoxydans in a patient with chronic kidney disease, refractory hypertension and sarcoidosis

Matthew S. Chorost, NANCY C. SMITH, Jack Hutter et al. · JMM Case Reports · 2018 · 19 citations · Full text